Supplementary Figure 6 from Anti-HER2, High-DAR Antibody Fragment–Drug Conjugates with a Glucuronide-Based MMAE Linker–Payload Demonstrate Superior Efficacy over IgG-Based ADCs

Ioanna Stamati; Gökhan Yahioglu; Soraya Diez-Posada; Anja Pomowski; Isabel Perez-Castro; A. Keith Stewart; Laura Bouché; Antony Constantinou; Benjamin J. Stenton; Savvas Saouros; Bryan Edwards; Sam Ness; Mahendra P. Deonarain

doi:10.1158/1535-7163.30029702

September 2, 2025Open Access

Supplementary Figure 6 from Anti-HER2, High-DAR Antibody Fragment–Drug Conjugates with a Glucuronide-Based MMAE Linker–Payload Demonstrate Superior Efficacy over IgG-Based ADCs

View Full Paper

Ask AI

Bookmark

Share

Key Points

Binding of high-DAR antibody drug conjugates showed superior efficacy compared to IgG-based ADCs.
Enhanced interactions with Fc-gamma receptors were observed in tests with human monocytes.
The study employed SPR to evaluate binding affinities of different antibody formats.
These results indicate potential for improved therapeutic outcomes in targeting HER2.

Abstract

Supplementary Figure 6 showing (a to c) binding of the scFv, FDC, IgG and ADC to CD64, CD32 and CD16 Fc-Gamma Receptors by SPR and (d) binding of the same test molecules to human monocytes extracted from PBMCs

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Stamati et al. (2025) studied this question.

synapsesocial.com/papers/68bb5f076d6d5674bcd02b39 https://doi.org/10.1158/1535-7163.30029702

View Full Paper

Ask AI

Bookmark

Share

Supplementary Figure 6 from Anti-HER2, High-DAR Antibody Fragment–Drug Conjugates with a Glucuronide-Based MMAE Linker–Payload Demonstrate Superior Efficacy over IgG-Based ADCs

Key Points

Abstract

Discussion

Cite This Study

Supplementary Figure 6 from Anti-HER2, High-DAR Antibody Fragment–Drug Conjugates with a Glucuronide-Based MMAE Linker–Payload Demonstrate Superior Efficacy over IgG-Based ADCs

Key Points

Abstract

Discussion

Cite This Study

Keep reading

Keep reading